Insilico, Tenacia expand AI CNS partnership in $94.75M deal
CURRENT BRIEF VERSION: Insilico Medicine and Tenacia Biotechnology said on March 26, 2026, that they’re expanding their AI-driven central nervous system collaboration, adding a second program and bringing the deal’s additional potential value to as much as $94.75 million. The partners said their initial March 2025 work used Insilico’s Pharma.AI platform and Tenacia’s CNS expertise and proprietary data to develop small-molecule inhibitors designed for strong blood-brain barrier penetration. Under the new agreement, they’ll use generative AI to advance another candidate with defined properties for difficult neurological diseases through the preclinical candidate stage. (prnewswire.com)
Why it matters: For veterinary professionals, this is another sign that AI-enabled drug discovery is moving beyond broad platform talk and into target- and property-specific CNS programs, where blood-brain barrier penetration remains a major challenge. While this deal is focused on human neurology, the same discovery approaches could eventually influence companion animal neurology, pain, and seizure pipelines, especially as companies look for faster ways to identify differentiated small molecules. It also lands against a backdrop of bigger validation for Insilico’s platform: the company has separately announced a multi-program AI drug discovery collaboration with Eli Lilly that carried up to $2.75 billion in potential value, including $115 million upfront, exclusive global rights for Lilly to certain preclinical oral candidates, and tiered royalties for Insilico. Tenacia’s growing footprint in neurology, including prior and recent Greater China partnerships in seizure and psychiatric disorders, suggests it’s positioning itself as a serious CNS commercialization and development partner in the region. (prnewswire.com)
What to watch: Watch for whether the expanded program reaches preclinical candidate nomination on the kind of compressed timeline Insilico has highlighted in other AI partnerships, and whether either company later discloses the target, indication, or geographic commercialization structure. Insilico’s larger Lilly deal is also a reminder to watch how often these AI collaborations move beyond discovery into licensing, global rights, and downstream commercial economics. (prnewswire.com)